Exploring the use of a Virus Based Anticancer Strategy for Lymphoma
A Clinical Trial of VSV-cIFNbeta-NIS Oncolytic Virotherapy for Canine B-Cell Lymphoma
Summary: This study explores the safety and effectiveness of a new virus-based therapy, developed at Mayo Clinic, for dogs with B-cell lymphoma.
Description: Lymphoma is one of the most commonly occurring malignant tumors in dogs. Though treatable, the disease often recurs and spreads. This study will determine the safety, efficacy and prognostic factors of a cancer-killing virus developed by researchers at the Mayo Clinic. Researchers at the University of Tennessee have already determined a safe dosing protocol for this virus in healthy dogs, and this clinical trial will test the dosing in dogs with B-cell lymphoma.
Using state-of-the-art cancer imaging, the study team will determine how successfully the virus spreads to sites of cancer. They will also study the dogs’ immune responses to the virus. This study provides the first robust assessment of a new anticancer strategy that has the potential to significantly improve quality of life and outcomes for dogs suffering from lymphoma.
Co-sponsored with the Morris Animal Foundation, Grant Number: D14CA-002
Dr. Amy K. LeBlanc
University of Tennessee